Neurotech International Ltd Asset Resilience Ratio

Latest as of December 2025: 0.22%

Neurotech International Ltd asset resilience ratio. Neurotech International Ltd (NTI) has an Asset Resilience Ratio of 0.22% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See NTI defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Liquid Assets

AU$15.00K
≈ $10.61K USD Cash + Short-term Investments

Total Assets

AU$6.81 Million
≈ $4.82 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Neurotech International Ltd (2016–2025)

Asset resilience ratio of Neurotech International Ltd from 2016 to 2025. This chart shows how Neurotech International Ltd's Asset Resilience Ratio has changed over time. Read debt load of Neurotech International Ltd for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Neurotech International Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Neurotech International Ltd assets under control.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$0.00 0%
Short-term Investments AU$15.00K 0.22%
Total Liquid Assets AU$15.00K 0.22%

Asset Resilience Insights

  • Limited Liquidity: Neurotech International Ltd maintains only 0.22% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Neurotech International Ltd Industry Peers by Asset Resilience Ratio

Compare Neurotech International Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Samsung Biologics Co Ltd
KO:207940
Biotechnology 15.21%
Abivax SA
PA:ABVX
Biotechnology 2.58%
Tubize-Fin
BR:TUB
Biotechnology 2.50%
BB Biotech AG
SW:BION
Biotechnology 92.97%
Sinocelltech Group Ltd
SHG:688520
Biotechnology 5.27%
Inner Mongolia Furui Med Sci
SHE:300049
Biotechnology 1.75%
Mineralys Therapeutics, Inc. Common Stock
NASDAQ:MLYS
Biotechnology 78.33%
GH Research PLC
NASDAQ:GHRS
Biotechnology 4.73%

Neurotech International Ltd Asset Resilience Ratio by Year (2016–2025)

Neurotech International Ltd asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Neurotech International Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 0.46% AU$15.00K
≈ $10.61K
AU$3.24 Million
≈ $2.29 Million
-77.44pp
2024-06-30 77.91% AU$9.52 Million
≈ $6.73 Million
AU$12.21 Million
≈ $8.64 Million
+39.95pp
2023-06-30 37.96% AU$2.02 Million
≈ $1.43 Million
AU$5.31 Million
≈ $3.76 Million
+37.21pp
2022-06-30 0.74% AU$15.00K
≈ $10.61K
AU$2.02 Million
≈ $1.43 Million
-95.69pp
2021-06-30 96.43% AU$4.83 Million
≈ $3.42 Million
AU$5.01 Million
≈ $3.54 Million
+48.40pp
2018-06-30 48.03% AU$2.21 Million
≈ $1.57 Million
AU$4.61 Million
≈ $3.26 Million
+3.50pp
2017-06-30 44.53% AU$2.21 Million
≈ $1.56 Million
AU$4.95 Million
≈ $3.50 Million
+41.28pp
2016-06-30 3.25% AU$500.00K
≈ $353.78K
AU$15.37 Million
≈ $10.88 Million
--
pp = percentage points

About Neurotech International Ltd

AU:NTI Australia Biotechnology
Market Cap
$19.44 Million
AU$27.47 Million AUD
Market Cap Rank
#25043 Global
#1038 in Australia
Share Price
AU$0.02
Change (1 day)
+6.25%
52-Week Range
AU$0.01 - AU$0.02
All Time High
AU$0.48
About

Neurotech International Limited, a clinical-stage biopharmaceutical development company, focuses on development of solutions for paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy in Australia. The company develops NTI164 to treat autism spectrum disorder, paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, paediatric acute… Read more